New licensee for Stem Cell Sciences' IRES technology
This article was originally published in Scrip
Stem Cell Sciences(SCS) has licensed its internal ribosome entry site (IRES) technology to an undisclosed top 20 pharmaceutical company. The deal follows a similar agreement that SCS signed in November, again with an undisclosed company, to license the IRES technology in return for $750,000 over six years as well as royalties (Scrip Online, November 24th, 2008). The value of the latest deal has not been revealed. Dr Alistair Riddell, SCS's CEO, said that he expected the company to make similar deals in the following months.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.